MedTrace Logo

A Study to Assess NEU-627 in Healthy Participants

NCT06900751 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-01-15

No results posted yet for this study

Summary

Phase 1, randomized, double-blind, placebo-controlled study of NEU-627 designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect.

Conditions

  • Healthy

Interventions

DRUG

NEU-627

Investigational medicinal product

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Neuron23 Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2025-10-28
Completion
2025-10-28

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900751 on ClinicalTrials.gov